BioSpace News Archive

Natera, Inc. today announced an analysis from the IMvigor011 study that was presented at the European Association of Urology (EAU) Congress 2024 in Paris, France.

Positive high-level results of the ADRIATIC Phase III trial showed AstraZeneca’s IMFINZI® demonstrated a statistically significant and clinically meaningful improvement in the dual primary endpoints of overall survival and progression-free survival in patients with limited-stage small cell lung cancer who had not progressed following concurrent chemoradiotherapy compared to placebo after cCRT.

89bio, Inc. announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 138,550 shares of the Company’s common stock to eight new employees on April 3, 2024.

NeuBase Therapeutics, Inc. reported that it received a notice on April 4, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that it was not in compliance with Nasdaq’s continued listing requirements under Nasdaq Listing Rule 5250 as a result of its failure to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 in a timely manner.

Syndax Pharmaceuticals announced that on April 1, 2024 the Company granted inducement awards to purchase up to 164,200 shares of common stock to ten new employees under the Company’s 2023 Inducement Plan.

Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, announced the grant of inducement awards to two new employees.

Predicine, Inc., a leading molecular insights company, announced the release of its innovative PredicineCARE™ NGS Kit.

Predicine, Inc., a leading molecular insights company, announced a collaboration with Apollomics, Inc.

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, announced that it granted equity awards on April 1, 2024, to six newly-hired, non-executive employees.

Inozyme Pharma, Inc. announced that it granted stock options to three new employees to purchase shares of the Company’s common stock, pursuant to the Company’s 2023 Inducement Stock Incentive Plan, as inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635.